Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

Clinical trials are a significant part of the drug development cycle. However, the process has remained unchanged in recent ...

Dr. Eugene Braunwald is often called the father of modern cardiology. He calls that an exaggeration. "Maybe I've been around ...

Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good afternoon, ladies and gentlemen, and welcome to the Inovio Third Quarter 2024 Financial Results Conference Call. At this time, all ...

Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first nine ...

The U.S. Food and Drug Administration (FDA) recently held a Patient Engagement Advisory Committee meeting focused on clinical trial informed ...

Although AI has the potential to improve and transform health care, doctors aren’t likely to leave the decision-making to ...

"We are also pleased with the steady progress of our pipeline, which included multiple filing acceptances in Europe and the ...

FRAMINGHAM, MA / ACCESSWIRE / November 13, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology ...

New real-world data from Providence, Illumina (NASDAQ: ILMN), and Microsoft Research reveals that Comprehensive Genomic Profiling (CGP), when done early in a cancer patient’s diagnosis, leads to ...